Please Wait a Moment
X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

04 Jan, 2022 | Return|

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

National Blood Donor Month

Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...

Read More >

Notification of Form Revisions to Implement on September 2, 2019

The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...

Read More >

Happy New Year!

We are very excited to launch our new website! Please take a few moments to click around and explore...

Read More >

Confirmatory Testing Delay for HIV-1 Western Blot and HIV-2 EIA

Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...

Read More >

Reminder- Check flights and cargo hours for the Christmas Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Reminder- The CTS Reentry form- CTS-00172 implements 7/2/18

Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...

Read More >